Robert W. Baird Downgrades Momenta Pharmaceuticals, Inc. (MNTA) to Hold

Robert W. Baird lowered shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) from a buy rating to a hold rating in a research note published on Friday. They currently have $15.00 price target on the biotechnology company’s stock, down from their prior price target of $22.00.

A number of other equities analysts also recently commented on the company. ValuEngine downgraded Momenta Pharmaceuticals from a hold rating to a sell rating in a report on Friday. J P Morgan Chase & Co restated a hold rating and issued a $14.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $14.00 price objective (down previously from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Barclays PLC restated an equal weight rating and issued a $16.00 price objective (down previously from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a hold rating to a buy rating and set a $20.00 price objective on the stock in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at 12.45 on Friday. Momenta Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $19.90. The stock’s market capitalization is $922.00 million. The firm’s 50-day moving average is $16.61 and its 200 day moving average is $15.82.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The firm had revenue of $23.57 million for the quarter, compared to the consensus estimate of $24.64 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The firm’s revenue was down 10.8% on a year-over-year basis. On average, analysts expect that Momenta Pharmaceuticals will post ($1.53) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Robert W. Baird Downgrades Momenta Pharmaceuticals, Inc. (MNTA) to Hold” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/robert-w-baird-downgrades-momenta-pharmaceuticals-inc-mnta-to-hold.html.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Craig A. Wheeler sold 16,953 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $16.94, for a total value of $287,183.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,663 shares of company stock worth $1,414,498. Corporate insiders own 4.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Eqis Capital Management Inc. acquired a new position in Momenta Pharmaceuticals during the third quarter valued at approximately $379,000. Public Employees Retirement System of Ohio acquired a new position in Momenta Pharmaceuticals during the second quarter valued at approximately $247,000. Piedmont Investment Advisors LLC acquired a new position in Momenta Pharmaceuticals during the second quarter valued at approximately $244,000. Ameritas Investment Partners Inc. grew its holdings in Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’

A number of other equities analysts also recently commented on the company. ValuEngine downgraded Momenta Pharmaceuticals from a hold rating to a sell rating in a report on Friday. J P Morgan Chase & Co restated a hold rating and issued a $14.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $14.00 price objective (down previously from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Barclays PLC restated an equal weight rating and issued a $16.00 price objective (down previously from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a hold rating to a buy rating and set a $20.00 price objective on the stock in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at 12.45 on Friday. Momenta Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $19.90. The stock’s market capitalization is $922.00 million. The firm’s 50-day moving average is $16.61 and its 200 day moving average is $15.82.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The firm had revenue of $23.57 million for the quarter, compared to the consensus estimate of $24.64 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The firm’s revenue was down 10.8% on a year-over-year basis. On average, analysts expect that Momenta Pharmaceuticals will post ($1.53) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Robert W. Baird Downgrades Momenta Pharmaceuticals, Inc. (MNTA) to Hold” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/robert-w-baird-downgrades-momenta-pharmaceuticals-inc-mnta-to-hold.html.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Craig A. Wheeler sold 16,953 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $16.94, for a total value of $287,183.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,663 shares of company stock worth $1,414,498. Corporate insiders own 4.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Eqis Capital Management Inc. acquired a new position in Momenta Pharmaceuticals during the third quarter valued at approximately $379,000. Public Employees Retirement System of Ohio acquired a new position in Momenta Pharmaceuticals during the second quarter valued at approximately $247,000. Piedmont Investment Advisors LLC acquired a new position in Momenta Pharmaceuticals during the second quarter valued at approximately $244,000. Ameritas Investment Partners Inc. grew its holdings in Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 834 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in Momenta Pharmaceuticals by 1.6% during the second quarter. California State Teachers Retirement System now owns 130,075 shares of the biotechnology company’s stock valued at $2,198,000 after purchasing an additional 2,099 shares during the last quarter. Institutional investors own 93.88% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply